Avelumab First-Line Maintenance Therapy: Managing Patients With Advanced Urothelial Carcinoma.

Background: The phase 3 of JAVELIN Bladder 100 trial demonstrated that avelumab first-line (1L) maintenance in addition to best supportive care significantly prolonged overall survival compared to best supportive care alone. It is now the standard of care for platinum-eligible patients with locally advanced or metastatic urothelial carcinoma that has not progressed with 1L platinum-containing chemotherapy.

Objectives: This article provides considerations for oncology nurses to effectively implement avelumab 1L maintenance treatment in the clinical setting.